NEW YORK, July 22, 2018 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
QUALCOMM Incorporated (NASDAQ:QCOM)
Class Period: January 31, 2018 – March 12, 2018
Lead Plaintiff Deadline: August 7, 2018
QUALCOMM Incorporated made materially false and/or misleading statements and/or failed to disclose that: (1) Qualcomm had secretly filed a unilateral notice with CFIUS in order to frustrate Broadcom’s attempt to acquire the Company; and (2) investors suffered damages as a result of defendants’ wrongful acts and omissions. On March 5, 2018, Broadcom announced that Qualcomm had filed a voluntary request for The Committee on Foreign Investment in the United States to initiate an investigation into Broadcom’s actions. Broadcom referred to this as a “blatant, desperate act by Qualcomm to entrench its incumbent board of directors and prevent its own stockholders from voting for Broadcom’s independent director nominees.”
To learn more about the QCOM class action go to: http://www.zlk.com/pslra-d/qualcomm-investigation?wire=3 or email firstname.lastname@example.org.
Recro Pharma, Inc. (NASDAQ:REPH)
Class Period: July 31, 2017 – May 23, 2018
Lead Plaintiff Deadline: July 23, 2018
During the class period, Recro Pharma, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s lead product, IV meloxicam, lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration (“FDA”) approval; and (ii) as a result, Recro Pharma’s public statements were materially false and misleading at all relevant times. On May 24, 2018, Recro Pharma announced that the FDA had declined to approve its New Drug Application (“NDA”) for IV meloxicam. In its Complete Response Letter, the FDA stated that the drug’s analgesic effects did not meet FDA expectations and raised questions related to chemistry, manufacturing and controls data.
To learn more about the REPH class action go to: http://www.zlk.com/pslra-d/recro-pharma-inc?wire=3 or email email@example.com.
PG&E Corporation (NYSE:PCG)
Class Period: April 29, 2015 – June 8, 2018
Lead Plaintiff Deadline: August 13, 2018
PG&E Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) PG&E had failed to maintain electricity transmission and distribution networks in compliance with safety requirements and regulations promulgated under state law; (ii) consequently, PG&E was in violation of state law regulation; (iii) PG&E’s electricity networks would cause numerous wildfires in California; and (iv) as a result of the foregoing, Defendants’ statements about the Company’s business and operations were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.